{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:27:35Z","timestamp":1790389655949,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00262-009-0769-5","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T11:11:26Z","timestamp":1254827486000},"page":"529-540","source":"Crossref","is-referenced-by-count":83,"title":["Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer"],"prefix":"10.1007","volume":"59","author":[{"given":"Barbara","family":"Seliger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Handke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Hofstaedter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"769_CR1","first-page":"159","volume-title":"World Health Organization, classification of tumours. Pathology and genetic. Tumours of the urinary system and male genital organs","author":"JI Epstein","year":"2004","unstructured":"Epstein JI, Algabe F, Allsbrook WC, Bastacky S (2004) Tumours of the prostate. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA et al (eds) World Health Organization, classification of tumours. Pathology and genetic. Tumours of the urinary system and male genital organs. IARC, Lyon, pp 159\u2013216"},{"key":"769_CR2","first-page":"345","volume":"2","author":"TC Thompson","year":"1990","unstructured":"Thompson TC (1990) Growth factors and oncogenes in prostate cancer. Cancer cells 2:345\u2013354","journal-title":"Cancer cells"},{"key":"769_CR3","first-page":"16","volume":"11","author":"M Risk","year":"2009","unstructured":"Risk M, Corman JM (2009) The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol 11:16\u201327","journal-title":"Rev Urol"},{"key":"769_CR4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00262-003-0377-8","volume":"52","author":"NG Chakraborty","year":"2003","unstructured":"Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC (2003) Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52:497\u2013505","journal-title":"Cancer Immunol Immunother"},{"key":"769_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2008.02.063","volume":"266","author":"YS Wang","year":"2008","unstructured":"Wang YS, Tsang YW, Chi CH, Cahng CC, Chu RM, Chi KH (2008) Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett 266:275\u2013285","journal-title":"Cancer Lett"},{"key":"769_CR6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2007.11.043","volume":"53","author":"A Kiessling","year":"2008","unstructured":"Kiessling A, F\u00fcssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53:694\u2013708","journal-title":"Eur Urol"},{"key":"769_CR7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/157488707781662724","volume":"2","author":"WC Olson","year":"2007","unstructured":"Olson WC, Heston WD, Rajasekaran AK (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2:182\u2013190","journal-title":"Rev Recent Clin Trials"},{"key":"769_CR8","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810\u20131815","journal-title":"Clin Cancer Res"},{"key":"769_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","volume":"69","author":"L Fong","year":"2009","unstructured":"Fong L, Kwek SS, O\u2019Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69:609\u2013615","journal-title":"Cancer Res"},{"key":"769_CR10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CGC.2007.n.017","volume":"5","author":"MR Theoret","year":"2007","unstructured":"Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL (2007) Phase I trail of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5:347\u2013350","journal-title":"Clin Genitourin Cancer"},{"key":"769_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PPO.0b013e318161bffa","volume":"14","author":"SF Slovin","year":"2008","unstructured":"Slovin SF (2008) Pitfalls or promise in prostate cancer immunotherapy which is winning? Cancer J 14:26\u201334","journal-title":"Cancer J"},{"key":"769_CR12","first-page":"2175","volume":"6","author":"PA Burch","year":"2000","unstructured":"Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovi\u0107 S (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175\u20132182","journal-title":"Clin Cancer Res"},{"key":"769_CR13","first-page":"1632","volume":"6","author":"JP Eder","year":"2000","unstructured":"Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW (2000) A phase I trial of a recombinant vaccina virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632\u20131638","journal-title":"Clin Cancer Res"},{"key":"769_CR14","first-page":"5160","volume":"59","author":"JW Simons","year":"2001","unstructured":"Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG (2001) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cell engineered to secrete granulocyte-macrophage colony-stimulating factor using ex\u00a0vivo gene transfer. Cancer Res 59:5160\u20135168","journal-title":"Cancer Res"},{"key":"769_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.immuni.2007.04.003","volume":"26","author":"GE Hammer","year":"2007","unstructured":"Hammer GE, Kanaseki T, Shastri N (2007) The final touches make perfect the peptide-MHC class I repertoire. Immunity 26:397\u2013406","journal-title":"Immunity"},{"key":"769_CR16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/ni1516","volume":"8","author":"PE Jensen","year":"2007","unstructured":"Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8:1041\u20131048","journal-title":"Nat Immunol"},{"key":"769_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-0-387-72005-0_13","volume":"601","author":"N Aptsiauri","year":"2007","unstructured":"Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601:123\u2013131","journal-title":"Adv Exp Med Biol"},{"key":"769_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1399-0039.2006.00777.x","volume":"1","author":"T Cabrera","year":"2007","unstructured":"Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 1:264\u2013268","journal-title":"Tissue Antigens"},{"key":"769_CR19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumor from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181\u2013273","journal-title":"Adv Immunol"},{"key":"769_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijc.21312","volume":"118","author":"B Seliger","year":"2006","unstructured":"Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129\u2013138","journal-title":"Int J Cancer"},{"key":"769_CR21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jnci\/87.4.280","volume":"87","author":"MG Sanda","year":"1995","unstructured":"Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280\u2013285","journal-title":"J Natl Cancer Inst"},{"key":"769_CR22","first-page":"1927","volume":"60","author":"HM Lee","year":"2000","unstructured":"Lee HM, Timme TL, Thompson TC (2000) Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60:1927\u20131933","journal-title":"Cancer Res"},{"key":"769_CR23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1464-410X.1994.tb09193.x","volume":"74","author":"JC Sharpe","year":"1994","unstructured":"Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS (1994) Modulated expression of human leukocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 74:609\u2013616","journal-title":"Br J Urol"},{"key":"769_CR24","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1158\/0008-5472.CAN-03-3734","volume":"65","author":"AF Setiadi","year":"2005","unstructured":"Setiadi AF, David MD, Chen SS, Hiscott J, Jefferies WA (2005) Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res 65:7485\u20137492","journal-title":"Cancer Res"},{"key":"769_CR25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.juro.2007.03.109","volume":"178","author":"H Kitamura","year":"2007","unstructured":"Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 178:692\u2013696","journal-title":"J Urol"},{"key":"769_CR26","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1089\/end.2008.9714","volume":"22","author":"JU Stolzenburg","year":"2008","unstructured":"Stolzenburg JU, Rabenalt R, Do M, Kallidonis P, Liatsikos EN (2008) Endoscopic extraperitoneal radical prostatectomy: the University of Leipzig experience of 2000 cases. J Endourol 22:2319\u20132325","journal-title":"J Endourol"},{"key":"769_CR27","first-page":"172","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"1997","unstructured":"Sobin LH, Wittekind C (1997) TNM classification of malignant tumours. Wiley-Liss, New York, pp 172\u2013175"},{"key":"769_CR28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ijc.21235","volume":"117","author":"G Kasper","year":"2005","unstructured":"Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Casta\u00f1os-V\u00e9lez E, Lehmann K (2005) Expression levels of putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. Int J Cancer 117:961\u2013973","journal-title":"Int J Cancer"},{"key":"769_CR29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2007.01.009","volume":"52","author":"JM van Oers","year":"2007","unstructured":"van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A (2007) FGFR3 mutations and normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumors. Eur Urol 52:760\u2013768","journal-title":"Eur Urol"},{"key":"769_CR30","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.4049\/jimmunol.137.7.2299","volume":"137","author":"NJ Stam","year":"1986","unstructured":"Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299\u20132306","journal-title":"J Immunol"},{"key":"769_CR31","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.171.4.1918","volume":"171","author":"F Perosa","year":"2003","unstructured":"Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918\u20131926","journal-title":"J Immunol"},{"key":"769_CR32","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.4049\/jimmunol.130.5.2471","volume":"30","author":"LA Lampson","year":"1983","unstructured":"Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 30:2471\u20132478","journal-title":"J Immunol"},{"key":"769_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1399-0039.2005.00462.x","volume":"66","author":"N Bandoh","year":"2005","unstructured":"Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66:185\u2013194","journal-title":"Tissue Antigens"},{"key":"769_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jim.2005.02.006","volume":"299","author":"X Wang","year":"2005","unstructured":"Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J. Immunol. Methods 299:139\u2013151","journal-title":"J. Immunol. Methods"},{"key":"769_CR35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1399-0039.2003.00114.x","volume":"62","author":"T Ogino","year":"2003","unstructured":"Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62:382\u2013393","journal-title":"Tissue Antigens"},{"key":"769_CR36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/hyb.1989.8.85","volume":"8","author":"M Temponi","year":"1989","unstructured":"Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85\u201395","journal-title":"Hybridoma"},{"key":"769_CR37","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/0008-5472.CAN-06-0029","volume":"66","author":"H Norell","year":"2006","unstructured":"Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2\/neu-specific immunity. Cancer Res 66:6387\u20136394","journal-title":"Cancer Res"},{"key":"769_CR38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.ju.0000094807.95420.fe","volume":"171","author":"D Atkins","year":"2004","unstructured":"Atkins D, Ferrone S, Schmahl GE, St\u00f6rkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171:885\u2013889","journal-title":"J Urol"},{"key":"769_CR39","first-page":"2011","volume":"59","author":"JE Armes","year":"1999","unstructured":"Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based-study. Cancer Res 59:2011\u20132017","journal-title":"Cancer Res"},{"key":"769_CR40","first-page":"1721","volume":"95","author":"B Seliger","year":"2003","unstructured":"Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, St\u00f6rkel S (2003) Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 95:1721\u20131727","journal-title":"Clin Cancer Res"},{"key":"769_CR41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","volume":"46","author":"RA Blandes","year":"1995","unstructured":"Blandes RA, Keating PJ, McWilliams LJ, George NJR, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681\u2013687","journal-title":"Urology"},{"key":"769_CR42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1097-0045(19971201)33:4<233::AID-PROS2>3.0.CO;2-I","volume":"33","author":"NH Bander","year":"1997","unstructured":"Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33:233\u2013239","journal-title":"Prostate"},{"key":"769_CR43","first-page":"2","volume":"3","author":"H Zhang","year":"2003","unstructured":"Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P (2003) Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2","journal-title":"Cancer Immun"},{"key":"769_CR44","doi-asserted-by":"crossref","first-page":"18763","DOI":"10.1074\/jbc.M511525200","volume":"281","author":"CC Chang","year":"2006","unstructured":"Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281:18763\u201318773","journal-title":"J Biol Chem"},{"key":"769_CR45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1084\/jem.169.1.309","volume":"169","author":"F Momburg","year":"1989","unstructured":"Momburg F, Koch S (1989) Selective loss of beta 2-microglobulin mRNA in human colon carcinoma. J Exp Med 169:309\u2013314","journal-title":"J Exp Med"},{"key":"769_CR46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ygyno.2007.02.016","volume":"105","author":"CF Vermeulen","year":"2007","unstructured":"Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ (2007) Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol 105:593\u2013599","journal-title":"Gynecol Oncol"},{"key":"769_CR47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9440(10)65321-7","volume":"154","author":"T Kageshita","year":"1999","unstructured":"Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745\u2013754","journal-title":"Am J Pathol"},{"key":"769_CR48","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1158\/0008-5472.CAN-04-3977","volume":"65","author":"Y Lou","year":"2005","unstructured":"Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65:7926\u20137933","journal-title":"Cancer Res"},{"key":"769_CR49","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-04-2146","volume":"11","author":"M Meissner","year":"2005","unstructured":"Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leucocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clinical Cancer Res 11:2552\u20132560","journal-title":"Clinical Cancer Res"},{"key":"769_CR50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","volume":"57","author":"AM Mehta","year":"2008","unstructured":"Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197\u2013206","journal-title":"Cancer Immunol Immunother"},{"key":"769_CR51","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.181.4.1459","volume":"181","author":"KL Wright","year":"1995","unstructured":"Wright KL, White LC, Kelly A, Beck S, Trowsdale J, Ting JP (1995) Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med 181:1459\u20131471","journal-title":"J Exp Med"},{"key":"769_CR52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.surg.2006.05.009","volume":"141","author":"CM Leys","year":"2007","unstructured":"Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR (2007) Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141:41\u201350","journal-title":"Surgery"},{"key":"769_CR53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, M\u00e9tivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54\u201361","journal-title":"Nat Med"},{"key":"769_CR54","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/cdd.2008.67","volume":"15","author":"T Panaretakis","year":"2008","unstructured":"Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15:1499\u20131509","journal-title":"Cell Death Differ"},{"key":"769_CR55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nbt0207-192","volume":"25","author":"C Clarke","year":"2007","unstructured":"Clarke C, Smyth MJ (2007) Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 25:192\u2013193","journal-title":"Nat Biotechnol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-009-0769-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0769-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T01:59:29Z","timestamp":1685152769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0769-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0769-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}